Table 3.

Prostate-specific antigen progression-free rate at 6 mo (eligible patients)

Progression status	n	%
Progression free at 6 mo	25	63
Progression within 6 mo	11	28
Other*	4	10
Total	40	–

^*Cases 98007 and 98030 started nonprotocol therapy prior to 6 mo; case 98041 experienced progression after 6 mo, but the last disease assessment documenting progression-free was prior to 6 mo. Case 98043 received step 2 treatment at 5 mo without meeting the criteria of progressive disease in step 1.